COMPANIES COVERED
TakedaDownload FREE Report Sample
Download Free sampleRecombinant antihemophilic factor?works by temporarily raising levels of?factor?VIII in the blood to aid in clotting.
Recombinant Antihemophilic Factor Market contains market size and forecasts of Recombinant Antihemophilic Factor in global, including the following market information:
Global Recombinant Antihemophilic Factor Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Recombinant Antihemophilic Factor Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Recombinant Antihemophilic Factor companies in 2021 (%)
The global Recombinant Antihemophilic Factor market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
200IU Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Recombinant Antihemophilic Factor include Takeda, Bayer, CSL, Pfizer, Biogen, Octapharma and NovoNordisk, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Recombinant Antihemophilic Factor manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Antihemophilic Factor Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Antihemophilic Factor Market Segment Percentages, by Type, 2021 (%)
200IU
250IU
Global Recombinant Antihemophilic Factor Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Antihemophilic Factor Market Segment Percentages, by Application, 2021 (%)
Hospital
Pharmacy
Global Recombinant Antihemophilic Factor Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Antihemophilic Factor Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Antihemophilic Factor revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Recombinant Antihemophilic Factor revenues share in global market, 2021 (%)
Key companies Recombinant Antihemophilic Factor sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Recombinant Antihemophilic Factor sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Takeda
Bayer
CSL
Pfizer
Biogen
Octapharma
NovoNordisk
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
